Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
4d Molecular Therapeutics Inc's Business Segments
4d Molecular Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 3
Countrys Reported
2
Revenue Share by Country -
- JP97%
- US3%
Revenue by Geographic Country -
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| JP | $ 3 | 97% |
| US | $ 0 | 3% |
Revenue by Product & Service Category -
- Collaboration and License Revenue100%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and License Revenue | $ 3 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of 4d Molecular Therapeutics Inc
4D Molecular Therapeutics Inc. (4DMT) is a biotechnology company specializing in gene therapy and targeted delivery of genes to specific tissues within the body. The company is dedicated to developing and commercializing transformative gene therapy products for patients with severe genetic diseases.
4DMT utilizes an innovative technology called the Therapeutic Vector Evolution platform, which enables the creation of adeno-associated virus (AAV) vectors with enhanced properties for precise gene delivery. AAV vectors are commonly used in gene therapy as vehicles to transport therapeutic genes into targeted cells.
The company's focus lies in addressing genetic diseases affecting large tissue areas, including cardiovascular, pulmonary, neuromuscular, and ophthalmic diseases. By leveraging their unique approach, 4DMT aims to deliver highly effective and long-lasting treatments to patients with some of the most challenging genetic diseases.
At the core of 4DMT's technology is their expertise in 4D structure-based design, an advanced approach that allows for the optimization of AAV vectors for specific therapeutic applications. This design process involves analyzing the structures of viral capsids and manipulating them to enhance their abilities to target specific tissues and cells in the body.
Moreover, 4DMT's therapeutic programs cover a wide range of diseases and disorders. Their pipeline includes potential treatments for diseases such as Fabry disease, Duchenne muscular dystrophy, cystic fibrosis, and multiple sclerosis, among others. By targeting these conditions at their source, 4DMT aims to provide patients with improved symptom management, disease modification, or potential cures.
The company also prioritizes collaboration and partnership with other research institutions, biotech companies, and academic organizations. This collaborative approach helps facilitate the advancement of gene therapy technologies and allows for the exploration of new therapeutic avenues.
In summary, 4D Molecular Therapeutics Inc. is a biotechnology company that focuses on gene therapy and developing innovative technologies for the targeted delivery of therapeutic genes. Their Therapeutic Vector Evolution platform, combined with a deep understanding of 4D structure-based design, positions them at the forefront of the gene therapy field. Through their extensive pipeline and collaborations, 4DMT aims to revolutionize the treatment of severe genetic diseases and make a significant impact on the lives of patients.
4DMT utilizes an innovative technology called the Therapeutic Vector Evolution platform, which enables the creation of adeno-associated virus (AAV) vectors with enhanced properties for precise gene delivery. AAV vectors are commonly used in gene therapy as vehicles to transport therapeutic genes into targeted cells.
The company's focus lies in addressing genetic diseases affecting large tissue areas, including cardiovascular, pulmonary, neuromuscular, and ophthalmic diseases. By leveraging their unique approach, 4DMT aims to deliver highly effective and long-lasting treatments to patients with some of the most challenging genetic diseases.
At the core of 4DMT's technology is their expertise in 4D structure-based design, an advanced approach that allows for the optimization of AAV vectors for specific therapeutic applications. This design process involves analyzing the structures of viral capsids and manipulating them to enhance their abilities to target specific tissues and cells in the body.
Moreover, 4DMT's therapeutic programs cover a wide range of diseases and disorders. Their pipeline includes potential treatments for diseases such as Fabry disease, Duchenne muscular dystrophy, cystic fibrosis, and multiple sclerosis, among others. By targeting these conditions at their source, 4DMT aims to provide patients with improved symptom management, disease modification, or potential cures.
The company also prioritizes collaboration and partnership with other research institutions, biotech companies, and academic organizations. This collaborative approach helps facilitate the advancement of gene therapy technologies and allows for the exploration of new therapeutic avenues.
In summary, 4D Molecular Therapeutics Inc. is a biotechnology company that focuses on gene therapy and developing innovative technologies for the targeted delivery of therapeutic genes. Their Therapeutic Vector Evolution platform, combined with a deep understanding of 4D structure-based design, positions them at the forefront of the gene therapy field. Through their extensive pipeline and collaborations, 4DMT aims to revolutionize the treatment of severe genetic diseases and make a significant impact on the lives of patients.
4D Molecular Therapeutics Inc (4DMT) is a pioneering company in the gene therapy sector, recognized for its innovative and targeted approach to developing vector-based gene therapies. Here’s an extensive overview of the segments, products, and services that define 4DMT’s operational landscape:
Segments
1. Research and Development (R&D):
- Vector Discovery Platform (VDP): At the core of 4DMT’s R&D efforts is its proprietary VDP, which plays a crucial role in identifying novel gene therapy targets. The platform employs advanced computational and experimental techniques to discover vectors tailored to specific therapeutic needs.
- Disease Biology Understanding: The R&D segment collaborates with researchers to deepen insights into the biological mechanisms of various diseases, facilitating the identification of ideal targets for gene therapy interventions.
2. Vector Development and Production:
- Viral Vector Creation: This segment is dedicated to the engineering of viral vectors, particularly adeno-associated viral (AAV) vectors, known for their safety and efficacy in gene delivery. 4DMT focuses on creating vectors that optimize the delivery of therapeutic genes to designated cells, enhancing treatment effectiveness.
- Scalability and Quality Control: 4DMT emphasizes robust processes that support the scalable production of vectors while maintaining rigorous quality control standards to meet both preclinical and clinical study requirements.
Products
1. Targeted Vector Library:
- 4DMT has established a comprehensive Targeted Vector Library, which comprises a wide array of AAV vectors engineered for specificity in targeting different tissues and cell types. This library serves as a fundamental resource for developing tailored gene therapies aimed at addressing a variety of genetic disorders.
2. Gene Therapy Candidates:
- Pipeline of Therapies: The company’s pipeline features several advanced gene therapy candidates, notably targeting ocular diseases (like retinal dystrophies), cardiovascular conditions (such as heart failure due to genetic mutations), and neurological disorders (including various types of muscular dystrophies). Each candidate is designed to deliver therapeutic genes that can potentially rectify underlying genetic anomalies.
- Innovation in Therapeutic Delivery: By leveraging optimized vector technology, these gene therapies aim to achieve high levels of gene expression in target tissues, providing robust therapeutic effects with minimized off-target effects.
Services
1. Vector Design and Optimization:
- Through its specialized services, 4DMT provides organizations with expert guidance in vector design and performance optimization. This involves customizing vectors to improve specificity for target cell types, enhancing delivery efficiency, and ensuring successful integration of therapeutic genes.
2. Collaboration and Licensing:
- 4DMT actively seeks partnerships with academic research institutions, biotechnology firms, and pharmaceutical companies to co-develop gene therapies. This includes licensing agreements that grant partners access to their Targeted Vector Library and expertise in vector design, allowing for collaborative advancements in gene therapy research.
3. Vector Manufacturing:
- The company operates a state-of-the-art manufacturing facility capable of producing high-quality AAV vectors at scale for both preclinical and clinical applications. This infrastructure supports the robust supply chains necessary for research and development activities as well as clinical trial executions.
- Custom Manufacturing Solutions: 4DMT can accommodate various production scales, responding flexibly to the needs of its partners and projects.
4. Regulatory Support:
- Navigating the intricacies of regulatory environments is critical in gene therapy development. 4DMT provides extensive regulatory support, including preparation for regulatory submissions and advice on how best to meet industry standards and requirements. This ensures that partners can effectively transition their therapies from preclinical stages through to clinical trials while maintaining compliance.
Conclusion
4D Molecular Therapeutics Inc stands at the forefront of gene therapy innovation, effectively leveraging its Vector Discovery Platform, Targeted Vector Library, and comprehensive services to revolutionize the treatment of a wide array of diseases. Through its focus on R&D, vector development, and strong partnerships, 4DMT aims to make significant contributions to the gene therapy landscape, offering novel solutions to patients with unmet medical needs.
Segments
1. Research and Development (R&D):
- Vector Discovery Platform (VDP): At the core of 4DMT’s R&D efforts is its proprietary VDP, which plays a crucial role in identifying novel gene therapy targets. The platform employs advanced computational and experimental techniques to discover vectors tailored to specific therapeutic needs.
- Disease Biology Understanding: The R&D segment collaborates with researchers to deepen insights into the biological mechanisms of various diseases, facilitating the identification of ideal targets for gene therapy interventions.
2. Vector Development and Production:
- Viral Vector Creation: This segment is dedicated to the engineering of viral vectors, particularly adeno-associated viral (AAV) vectors, known for their safety and efficacy in gene delivery. 4DMT focuses on creating vectors that optimize the delivery of therapeutic genes to designated cells, enhancing treatment effectiveness.
- Scalability and Quality Control: 4DMT emphasizes robust processes that support the scalable production of vectors while maintaining rigorous quality control standards to meet both preclinical and clinical study requirements.
Products
1. Targeted Vector Library:
- 4DMT has established a comprehensive Targeted Vector Library, which comprises a wide array of AAV vectors engineered for specificity in targeting different tissues and cell types. This library serves as a fundamental resource for developing tailored gene therapies aimed at addressing a variety of genetic disorders.
2. Gene Therapy Candidates:
- Pipeline of Therapies: The company’s pipeline features several advanced gene therapy candidates, notably targeting ocular diseases (like retinal dystrophies), cardiovascular conditions (such as heart failure due to genetic mutations), and neurological disorders (including various types of muscular dystrophies). Each candidate is designed to deliver therapeutic genes that can potentially rectify underlying genetic anomalies.
- Innovation in Therapeutic Delivery: By leveraging optimized vector technology, these gene therapies aim to achieve high levels of gene expression in target tissues, providing robust therapeutic effects with minimized off-target effects.
Services
1. Vector Design and Optimization:
- Through its specialized services, 4DMT provides organizations with expert guidance in vector design and performance optimization. This involves customizing vectors to improve specificity for target cell types, enhancing delivery efficiency, and ensuring successful integration of therapeutic genes.
2. Collaboration and Licensing:
- 4DMT actively seeks partnerships with academic research institutions, biotechnology firms, and pharmaceutical companies to co-develop gene therapies. This includes licensing agreements that grant partners access to their Targeted Vector Library and expertise in vector design, allowing for collaborative advancements in gene therapy research.
3. Vector Manufacturing:
- The company operates a state-of-the-art manufacturing facility capable of producing high-quality AAV vectors at scale for both preclinical and clinical applications. This infrastructure supports the robust supply chains necessary for research and development activities as well as clinical trial executions.
- Custom Manufacturing Solutions: 4DMT can accommodate various production scales, responding flexibly to the needs of its partners and projects.
4. Regulatory Support:
- Navigating the intricacies of regulatory environments is critical in gene therapy development. 4DMT provides extensive regulatory support, including preparation for regulatory submissions and advice on how best to meet industry standards and requirements. This ensures that partners can effectively transition their therapies from preclinical stages through to clinical trials while maintaining compliance.
Conclusion
4D Molecular Therapeutics Inc stands at the forefront of gene therapy innovation, effectively leveraging its Vector Discovery Platform, Targeted Vector Library, and comprehensive services to revolutionize the treatment of a wide array of diseases. Through its focus on R&D, vector development, and strong partnerships, 4DMT aims to make significant contributions to the gene therapy landscape, offering novel solutions to patients with unmet medical needs.